HIV genetic diversity and drug resistance

Viruses

Volumn 2, Issue 2, 2010, Pages 503-531

  Santos, André F ^a   Soares, Marcelo A ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Clinical response; Drug resistance; Genetic diversity; HIV 1; Subtypes

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CD4 LYMPHOCYTE COUNT; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DYNAMICS; NONHUMAN; PREVALENCE; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; STRUCTURAL GENE; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79851516791     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2020503     Document Type: Review

References (139)

1. Gallo, R.C.; Sarin, P.S.; Gelmann, E.P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V.S.; Mann, D.; Sidhu, G.D.; Stahl, R.E.; Zolla-Pazner, S.; Leibowitch, J.; Popovic, M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983, 220, 865-867.
2. Barré-Sinouss, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868-871.
3. Korber, B.; Muldoon, M.; Theiler, J.; Gao, F.; Gupta, R.; Lapedes, A.; Hahn, B.H.; Wolinsky, S.; Bhattacharya, T. Timing the ancestor of the HIV-1 pandemic strains. Science 2000, 288, 1789-1796.
4. Worobey, M.; Gemmel, M.; Teuwen, D.E.; Haselkorn, T.; Kunstman, K.; Bunce, M.; Muyembe, J.J.; Kabongo, J.M.; Kalengayi, R.M.; Van Marck, E.; Gilbert, M.T.; Wolinsky, S.M. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455, 661-664.
5. Joint United Nations Program on HIV/AIDS. Report on the Global AIDS Epidemic. World Health Organization: Geneva, Switzerland, 2008. Available online: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp (accessed on 15 July 2009).
6. Taubenberger, J.K.; Reid, A.H.; Janczewski, T.A.; Fanning, T.G. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2001, 356, 1829-1839.
7. Liégeois, F.; Lafay, B.; Formenty, P.; Locatelli, S.; Courgnaud, V.; Delaporte, E.; Peeters, M. Full-length genome characterization of a novel simian immunodeficiency virus lineage (SIVolc) from olive Colobus (Procolobus verus) and new SIVwrcPbb strains from Western Red Colobus (Piliocolobus badius badius) from the Tai Forest in Ivory Coast. J. Virol. 2009, 83, 428-439.
8. Locatelli, S.; Lafay, B.; Liegeois, F.; Ting, N.; Delaporte, E.; Peeters, M. Full molecular characterization of a simian immunodeficiency virus, SIVwrcpbt from Temminck's red colobus (Piliocolobus badius temminckii) from Abuko Nature Reserve, The Gambia. Virology 2008, 376, 90-100.
9. Kalish, M.L.; Wolfe, N.D.; Ndongmo, C.B.; McNicholl, J.; Robbins, K.E.; Aidoo, M.; Fonjungo, P.N.; Alemnji, G.; Zeh, C.; Djoko, C.F.; Mpoudi-Ngole, E.; Burke, D.S.; Folks, T.M. Central African hunters exposed to simian immunodeficiency virus. Emerg. Infect. Dis. 2005, 11, 1928-1930.
10. Wolfe, N.D.; Switzer, W.M.; Carr, J.K.; Bhullar, V.B.; Shanmugam, V.; Tamoufe, U.; Prosser, A.T.; Torimiro, J.N.; Wright, A.; Mpoudi-Ngole, E.; McCutchan, F.E.; Birx, D.L.; Folks, T.M.; Burke, D.S.; Heneine, W. Naturally acquired simian retrovirus infections in central African hunters. Lancet 2004, 363, 932-937.
11. Gao, F.; Bailes, E.; Robertson, D.L.; Chen, Y.; Rodenburg, C.M.; Michael, S.F.; Cummins, L.B.; Arthur, L.O.; Peeters, M.; Shaw, G.M.; Sharp, P.M.; Hahn, B.H. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397, 436-441.
12. Gao, F.; Yue, L.; White, A.T.; Pappas, P.G.; Barchue, J.; Hanson, A.P.; Greene, B.M.; Sharp, P.M.; Shaw, G.M.; Hahn, B.H. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 1992, 358, 495-499.
13. Van Heuverswyn, F.; Li, Y.; Neel, C.; Bailes, E.; Keele, B.F.; Liu, W.; Loul, S.; Butel, C.; Liegeois, F.; Bienvenue, Y.; Ngolle, E.M.; Sharp, P.M.; Shaw, G.M.; Delaporte, E.; Hahn, B.H.; Peeters, M. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006, 444, 164.
14. Takehisa, J.; Kraus, M.H.; Ayouba, A.; Bailes, E.; Van Heuverswyn, F.; Decker, J.M.; Li, Y.; Rudicell, R.S.; Learn, G.H.; Neel, C.; Ngole, E.M.; Shaw, G.M.; Peeters, M.; Sharp, P.M.; Hahn, B.H. Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J. Virol. 2009, 83, 1635-1648.
15. Ayouba, A.; Mauclère, P.; Martin, P.M.; Cunin, P.; Mfoupouendoun, J.; Njinku, B.; Souquières, S.; Simon, F. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg. Infect. Dis. 2001, 7, 466-467.
16. Brennan, C.A.; Bodelle, P.; Coffey, R.; Devare, S.G.; Golden, A.; Hackett, J. Jr.; Harris, B.; Holzmayer, V.; Luk, K.C.; Schochetman, G.; Swanson, P.; Yamaguchi, J.; Vallari, A.; Ndembi, N.; Ngansop, C.; Makamche, F.; Mbanya, D.; Gürtler, L.G.; Zekeng, L.; Kaptué, L. The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J. Acquir. Immune Defic. Syndr. 2008, 49, 432-439.
17. Simon, F.; Mauclère, P.; Roques, P.; Loussert-Ajaka, I.; Müller-Trutwin, M.C.; Saragosti, S.; Georges-Courbot, M.C.; Barré-Sinoussi, F.; Brun-Vénizet, F. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat. Med. 1998, 4, 1032-1037.
18. Roques, P.; Robertson, D.L.; Souquière, S.; Apetrei, C.; Nerrienet, E.; Barré-Sinoussi, F.; Müller-Trutwin, M.; Simon, F. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N. AIDS 2004, 18, 1371-1381.
19. Ayouba, A.; Souquières, S.; Njinku, B.; Martin, P.M.; Müller-Trutwin, M.C.; Roques, P.; Barré-Sinoussi, F.; Mauclère, P.; Simon, F.; Nerrienet, E. HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS 2000, 14, 2623-2625.
20. Bodelle, P.; Vallari, A.; Coffey, R.; McArthur, C.P.; Beyeme, M.; Devare, S.G.; Schochetman, G.; Brennan, C.A. Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. AIDS Res. Hum. Retroviruses 2004, 20, 902-908.
21. Plantier, J.C.; Leoz, M.; Dickerson, J.E.; De Oliveira, F.; Cordonnier, F.; Lemée, V.; Damond, F.; Robertson, D.L.; Simon, F. A new human immunodeficiency virus derived from gorillas. Nat. Med. 2009, 15, 871-872.
22. HIV sequence database. The Human Retroviruses and AIDS 1994 Compendium. III23-III33. Available online: http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/ 94compendium.html (accessed on 18 July 2009).
23. Janssens, W.; Heyndrickx, L.; Fransen, K.; Motte, J.; Peeters, M.; Nkengasong, J.N.; Ndumbe, P.M.; Delaporte, E.; Perret, J.L.; Atender, C.; Piot, P.; van der Groen, G. Genetic and phylogenetic analysis of env subtypes G and H in central Africa. AIDS Res. Hum. Retroviruses 1994, 10, 877-879.
24. Kostrikis, L.G.; Bagdades, E.; Cao, Y.; Zhang, L.; Dimitriou, D.; Ho, D.D. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J. Virol. 1995, 69, 6122-6130.
25. Laukkanen, T.; Albert, J.; Liitsola, K.; Green, S.D.; Carr, J.K.; Leitner, T.; McCutchan, F.E.; Salminen, M.O. Virtually full-length sequences of HIV type 1 subtype J reference strains. AIDS Res. Hum. Retroviruses 1999, 15, 293-297.
26. Triques, K.; Bourgeois, A.; Vidal, N.; Mpoudi-Ngole, E.; Mulanga-Kabeya, C.; Nzilambi, N.; Torimiro, N.; Saman, E.; Delaporte, E.; Peeters, M. Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K. AIDS Res. Hum. Retroviruses 2000, 16, 139-151.
27. Gao, F.; Robertson, D.L.; Morrison, S.G.; Hui, H.; Craig, S.; Decker, J.; Fultz, P.N.; Girard, M.; Shaw, G.M.; Hahn, B.H.; Sharp, P.M. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 1996, 70, 7013-7029.
28. Carr, J.K.; Salminen, M.O.; Albert, J.; Sanders-Buell, E.; Gotte, D.; Birx, D.L.; McCutchan, F.E. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 1998, 247, 22-31.
29. McCutchan, F.E.; Carr, J.K.; Bajani, M.; Sanders-Buell, E.; Harry, T.O.; Stoeckli, T.C.; Robbins, K.E.; Gashau, W.; Nasidi, A.; Janssens, W.; Kalish, M.L. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology 1999, 254, 226-234.
30. Gao, F.; Robertson, D.L.; Carruthers, C.D.; Li, Y.; Bailes, E.; Kostrikis, L.G.; Salminen, M.O.; Bibollet-Ruche, F.; Peeters, M.; Ho, D.D.; Shaw, G.M.; Sharp, P.M.; Hahn, B.H. An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). J. Virol. 1998, 72, 10234-10241.
31. Nasioulas, G.; Paraskevis, D.; Magiorkinis, E.; Theodoridou, M.; Hatzakis, A. Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. AIDS Res. Hum. Retroviruses 1999, 15, 745-758.
32. Robertson, D.L.; Anderson, J.P.; Bradac, J.A.; Carr, J.K.; Foley, B.; Funkhouser, R.K.; Gao, F.; Hahn, B.H.; Kalish, M.L.; Kuiken, C.; Learn, G.H.; Leitner, T.; McCutchan, F.; Osmanov, S.; Peeters, M.; Pieniazek, D.; Salminen, M.; Sharp, P.M.; Wolinsky, S.; Korber, B. HIV-1 nomenclature proposal. Science 2000, 288, 55-56.
33. Gao, F.; Vidal, N.; Li, Y.; Trask, S.A.; Chen, Y.; Kostrikis, L.G.; Ho, D.D.; Kim, J.; Oh, M.D.; Choe, K.; Salminen, M.; Robertson, D.L.; Shaw, G.M.; Hahn, B.H.; Peeters, M. Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res. Hum. Retroviruses 2001, 17, 675-688.
34. Meloni, S.T.; Kim, B.; Sankalé, J.L.; Hamel, D.J.; Tovanabutra, S.; Mboup, S.; McCutchan, F.E.; Kanki, P.J. Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J. Virol. 2004, 78, 12438-12445.
35. Triques, K.; Bourgeois, A.; Saragosti, S.; Vidal, N.; Mpoudi-Ngole, E.; Nzilambi, N.; Apetrei, C.; Ekwalanga, M.; Delaporte, E.; Peeters, M. High diversity of HIV-1 subtype F strains in Central Africa. Virology 1999, 259, 99-109.
36. Hemelaar, J.; Gouws, E.; Ghys, P.D.; Osmanov, S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20, W13-W23.
37. Santos, A.F.; Schrago, C.G.; Martinez, A.M.; Mendoza-Sassi, R.; Silveira, J.; Sousa, T.M.; Lengruber, R.B.; Soares, E.A.; Sprinz, E.; Soares, M.A. Epidemiologic and evolutionary trends of HIV-1 CRF31_BC-related strains in southern Brazil. J. Acquir. Immune Defic. Syndr. 2007, 45, 328-333.
38. Salemi, M.; de Oliveira, T.; Soares, M.A.; Pybus, O.; Dumans, A.T.; Vandamme, A.M.; Tanuri, A.; Cassol, S.; Fitch, W.M. Different epidemic potentials of the HIV-1B and C subtypes. J. Mol. Evol. 2005, 60, 598-605.
39. Bello, G.; Passaes, C.P.; Guimarães, M.L.; Lorete, R.S.; Matos Almeida, S.E.; Medeiros, R.M.; Alencastro, P.R.; Morgado, M.G. Origin and evolutionary history of HIV-1 subtype C in Brazil. AIDS 2008, 22, 1993-2000.
40. Soares, E.A.; Martínez, A.M.; Souza, T.M.; Santos, A.F.; Da Hora, V.; Silveira, J.; Bastos, F.I.; Tanuri, A.; Soare,s M.A. HIV-1 subtype C dissemination in southern Brazil. AIDS 2005, 19 (Suppl. 4), S81-S86.
41. Brígido, L.F.; Nunes, C.C.; Oliveira, C.M.; Knoll, R.K.; Ferreira, J.L.; Freitas, C.A.; Alves, M.A.; Dias, C.; Rodrigues, R.; Research Capacity Program. HIV type 1 C and C B Pol recombinants prevail at the cities with the highest AIDS prevalence rate in Brazil. AIDS Res. Hum. Retroviruses 2007, 23, 1579-1586.
42. Locateli, D.; Stoco, P.H.; de Queiroz, A.T.; Alcântara, L.C.; Ferreira, L.G.; Zanetti, C.R.; Rodrigues, R.; Grisard, E.C.; Pinto, A.R. Molecular epidemiology of HIV-1 in Santa Catarina State confirms increases of subtype C in Southern Brazil. J. Med. Virol. 2007, 79, 1455-1463.
43. Soares, E.A.; Santos, R.P.; Pellegrini, J.A.; Sprinz, E.; Tanuri, A.; Soares, M.A. Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J. Acquir. Immune Defic. Syndr. 2003, 34, 520-526.
44. Williamson, C.; Engelbrecht, S.; Lambrick, M.; van Rensburg, E.J.; Wood, R.; Bredell, W.; Williamson, A.L. HIV-1 subtypes in different risk groups in South Africa. Lancet 1995, 346, 782.
45. van Harmelen, J.; Wood, R.; Lambrick, M.; Rybicki, E.P.; Williamson, A.L.; Williamson, C. An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa. AIDS 1997, 11, 81-87.
46. Pomerantz, R.J.; Horn, D.L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9, 867-873.
47. Gulick, R.M.; Meibohm, A.; Havlir, D.; Eron, J.J.; Mosley, A.; Chodakewitz, J.A.; Isaacs, R.; Gonzalez, C.; McMahon, D.; Richman, D.D.; Robertson, M.; Mellors, J.W. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003, 17, 2345-2349.
48. Bussmann, H.; Wester, C.W.; Ndwapi, N.; Grundmann, N.; Gaolathe, T.; Puvimanasinghe, J.; Avalos, A.; Mine, M.; Seipone, K.; Essex, M.; Degruttola, V.; Marlink, R.G. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008, 22, 2303-2311.
49. Larder, B.A.; Darby, G.; Richman, D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243, 1731-1734.
50. Volberding, P.A.; Lagakos, S.W.; Grimes, J.M.; Stein, D.S.; Rooney, J.; Meng, T.C.; Fischl, M.A.; Collier, A.C.; Phair, J.P.; Hirsch, M.S.; Hardy, W.D.; Balfour, H.H.; Reichman, R.C; For the AIDS Clinical Trials Group. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N. Engl. J. Med. 1995, 333, 401-407.
51. Fitzgibbon, J.E.; Farnham, A.E.; Sperber, S.J.; Kim, H.; Dubin, D.T. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J. Virol. 1993, 67, 7271-7275.
52. Preston, B.D.; Poiesz, B.J.; Loeb, L.A. Fidelity of HIV-1 reverse transcriptase. Science 1988, 242, 1168-1171.
53. Perelson, A.S.; Neumann, A.U.; Markowitz, M.; Leonard, J.M.; Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271, 1582-1586.
54. Rambaut, A.; Posada, D.; Crandall, K.A.; Holmes, E.C. The causes and consequences of HIV evolution. Nat. Rev. Genet. 2004, 5, 52-61.
55. Johnson, V.A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H.F.; Kuritzkes, D.R.; Pillay, D.; Schapiro, J.M.; Richman, D.D. Update of the Drug Resistance Mutations in HIV-1. Top. HIV Med. 2008, 16, 138-145.
56. Martinez-Picado, J.; Savara, A.V.; Shi, L.; Sutton, L.; D'Aquila, R.T. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000, 275, 318-322.
57. Iglesias-Ussel, M.D.; Casado, C.; Yuste, E.; Olivares, I.; López-Galíndez, C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol. 2002, 83, 93-101.
58. Miller, M.D.; Lamy, P.D.; Fuller, M.D.; Mulato, A.S.; Margot, N.A.; Cihlar, T.; Cherrington, J.M. Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. Mol. Pharmacol. 1998, 54, 291-297.
59. White, K.L.; Margot, N.A.; Wrin, T.; Petropoulos, C.J.; Miller, M.D.; Naeger, L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 2002, 46, 3437-3446.
60. Martinez-Picado, J.; Savara, A.V.; Sutton, L.; D'Aquila, R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73, 3744-3752.
61. Nijhuis, M.; Schuurman, R.; de Jong, D.; Erickson, J.; Gustchina, E.; Albert, J.; Schipper, P.; Gulnik, S.; Boucher, C.A. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13, 2349-2359.
62. Mammano, F.; Trouplin, V.; Zennou, V.; Clavel, F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 2000, 74, 8524-8531.
63. Nakahara, K.; Wakasa-Morimoto, C.; Kobayashi, M.; Miki, S.; Noshi, T.; Seki, T.; Kanamori-Koyama, M.; Kawauchi, S.; Suyama, A.; Fujishita, T.; Yoshinaga, T.; Garvey, E.P.; Johns, B.A.; Foster, S.A.; Underwood, M.R.; Sato, A.; Fujiwara, T. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2009, 81, 141-146.
64. Palma, A.C.; Araújo, F.; Duque, V.; Borges, F.; Paixão, M.T.; Camacho, R.; Portuguese SPREAD Network. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect. Genet. Evol. 2007, 7, 391-398.
65. Tatt, I.D.; Barlow, K.L.; Clewley, J.P.; Gill, O.N.; Parry, J.V. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J. Acquir. Immune Defic. Syndr. 2004, 36, 1092-1099.
66. Descamps, D.; Chaix, M.L.; André, P.; Brodard, V.; Cottalorda, J.; Deveau, C.; Harzic, M.; Ingrand, D.; Izopet, J.; Kohli, E.; Masquelier, B.; Mouajjah, S.; Palmer, P.; Pellegrin, I.; Plantier, J.C.; Poggi, C.; Rogez, S.; Ruffaut, A.; Schneider, V.; Signori-Schück, A.; Tamalet, C.; Wirden, M.; Rouzioux, C.; Brun-Venizet, F.; Meyer, L.; Costagliola, D. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J. Acquir. Immune Defic. Syndr. 2005, 38, 545-552.
67. Paraskevis, D.; Magiorkinis, E.; Magiorkinis, G.; Sypsa, V.; Paparizos, V.; Lazanas, M.; Gargalianos, P.; Antoniadou, A.; Panos, G.; Chrysos, G. et al. Multicentre Study on HIV Heterogeneity. Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. J. Infect. Dis. 2007, 196, 1167-1176.
68. Ntemgwa, M.L.; Toni, T.D.; Brenner, B.G.; Camacho, R.J.; Wainberg, M.A. Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2 (HIV-2). Antimicrob. Agents Chemother. 2009, 53, 3611-3619.
69. Witvrouw, M.; Pannecouque, C.; Switzer, W.M.; Folks, T.M.; De Clercq, E.; Heneine, W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 2004, 9, 57-65.
70. Reid, P.; MacInnes, H.; Cong, M.E.; Heneine, W.; García-Lerma, J.G. Natural resistance of human immunodeficiency virus type 2 to zidovudine. Virology 2005, 336, 251-264.
71. Hizi, A.; Tal, R.; Shaharabany, M.; Currens, M.J.; Boyd, M.R.; Hughes, S.H.; McMahon, J.B. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob. Agents Chemother. 1993, 37, 1037-1042.
72. Descamps, D.; Collin, G.; Letourneur, F.; Apetrei, C.; Damond, F.; Loussert-Ajaka, I.; Simon, F.; Saragosti, S.; Brun-Vézinet, F. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. 1997, 71, 8893-8898.
73. Pieniazek, D.; Rayfield, M.; Hu, D.J.; Nkengasong, J.; Wiktor, S.Z.; Downing, R.; Biryahwaho, B.; Mastro, T.; Tanuri, A.; Soriano, V.; Lal, R.; Dondero, T. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000, 14, 1489-1495.
74. Vergne, L.; Peeters, M.; Mpoudi-Ngole, E.; Bourgeois, A.; Liegeois, F.; Toure-Kane, C.; Mboup, S.; Mulanga-Kabeya, C.; Saman, E.; Jourdan, J.; Reynes, J.; Delaporte, E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J. Clin. Microbiol. 2000, 38, 3919-3925.
75. Fonjungo, P.N.; Mpoudi, E.N.; Torimiro, J.N.; Alemnji, G.A.; Eno, L.T.; Lyonga, E.J.; Nkengasong, J.N.; Lal, R.B.; Rayfield, M.; Kalish, Folks, T.M; Pieniazek, D. Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features. J. Clin. Microbiol. 2002, 40, 837-845.
76. Holguín, A.; Alvarez, A.; Soriano, V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 2002, 16, 1163-1170.
77. Kantor, R.; Katzenstein, D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003, 5, 25-35.
78. Palmer, S.; Margot, N.; Gilbert, H.; Shaw, N.; Buckheit, R. Jr.; Miller, M. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res. Hum. Retroviruses 2001, 17, 1167-1173.
79. Vergne, L.; Stuyver, L.; Van Houtte, M.; Butel, C.; Delaporte, E.; Peeters, M. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J. Clin. Virol. 2006, 36, 43-49.
80. Holguín, A.; Paxinos, E.; Hertogs, K.; Womac, C.; Soriano, V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol. 2004, 31, 215-220.
81. Grossman, Z.; Paxinos, E.E.; Averbuch, D.; Maayan, S.; Parkin, N.T.; Engelhard, D.; Lorber, M.; Istomin, V.; Shaked, Y.; Mendelson, E.; Ram, D.; Petropoulos, C.J.; Schapiro, J.M. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 2004, 48, 2159-2165.
82. Poveda, E.; de Mendoza, C.; Parkin, N.; Choe, S.; García-Gasco, P.; Corral, A.; Soriano, V. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008, 22, 611-616.
83. Abecasis, A.B.; Deforche, K.; Bacheler, L.T.; McKenna, P.; Carvalho, A.P.; Gomes, P.; Vandamme, A.M.; Camacho, R.J. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther. 2006, 11, 581-589.
84. Agwale, S.M.; Zeh, C.; Paxinos, E.; Odama, L.; Pienazek, D.; Wambebe, C.; Kalish, M.L.; Ziermann, R. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res. Hum. Retroviruses 2006, 22, 22-26.
85. Cane, P.A.; de Ruiter, A.; Rice, P.; Wiselka, M.; Fox, R.; Pillay, D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom. J. Clin. Microbiol. 2001, 39, 2652-2654.
86. Sirivichayakul, S.; Ruxrungtham, K.; Ungsedhapand, C.; Techasathit, W.; Ubolyam, S.; Chuenyam, T.; Emery, S.; Cooper, D.; Lange, J.; Phanuphak, P. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003, 17, 1889-1896.
87. Apetrei, C.; Descamps, D.; Collin, G.; Robertson, D.L.; Pandrea, I.; Groza, P.; Prisecariu, L.; Teodorescu, I.; Luca, V.; Brun-Vézinet, F. HIV type 1 diversity in northeastern Romania in 200-2001 based on phylogenic analysis of pol sequences from patient failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 2003, 19, 1155-1161.
88. Hsu, L.Y.; Subramaniam, R.; Bacheler, L.; Paton, N.I. Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment-naive and -experienced patients in Singapore. J. Acquir. Immune Defic. Syndr. 2005, 38, 5-13.
89. Kantor, R.; Katzenstein, D.A.; Efron, B.; Carvalho, A.P.; Wynhoven, B.; Cane, P.; Clarke, J.; Sirivichayakul, S.; Soares, M.A.; Snoeck, J.; Pillay, C.; Rudich, H.; Rodrigues, R.; Holguin, A.; Ariyoshi, K.; Bouzas, M.B.; Cahn, P.; Sugiura, W.; Soriano, V.; Brigido, L.F.; Grossman, Z.; Morris, L.; Vandamme, A.M.; Tanuri, A.; Phanuphak, P.; Weber, J.N.; Pillay, D.; Harrigan, P.R.; Camacho, R.; Schapiro, J.M.; Shafer, R.W. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005, 2, e112.
90. Doualla-Bell, F.; Avalos, A.; Gaolathe, T.; Mine, M.; Gaseitsiwe, S.; Ndwapi, N.; Novitsky, V.A.; Brenner, B.; Oliveira, M.; Moisi, D.; Moffat, H.; Thior, I.; Essex, M.; Wainberg, M.A. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrob. Agents Chemother. 2006, 50, 2210-2213.
91. Ariyoshi, K.; Matsuda, M.; Miura, H.; Tateishi, S.; Yamada, K.; Sugiura, W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune Defic. Syndr. 2003, 33, 336-342.
92. Dumans, A.T.; Barreto, C.C.; Santos, A.F.; Arruda, M.; Sousa, T.M.; Machado, E.S.; Sabino, E.C.; Brindeiro, R.M.; Tanuri, A.; Duarte, A.J.; Soares, M.A. Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infect. Genet. Evol. 2009, 9, 62-70.
93. Novitsky, V.; Wester, C.W.; DeGruttola, V.; Bussmann, H.; Gaseitsiwe, S.; Thomas, A.; Moyo, S.; Musonda, R.; Van Widenfelt, E.; Marlink, R.G.; Essex, M. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res. Hum. Retroviruses 2007, 23, 868-878.
94. Tebit, D.M.; Sangaré, L.; Makamtse, A.; Yameogo, S.; Somlare, H.; Bado, G.; Kouldiaty, B.G.; Sathiandee, K.; Tiba, F.; Sanou, I.; Ouédraogo-Traoré, R.; Zoungrana, L.; Diallo, I.; Drabo, J.Y.; Kraüsslich, H.G. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. J. Acquir. Immune. Defic. Syndr. 2008, 49, 17-25.
95. Gupta, R.K.; Chrystie, I.L.; O'Shea, S.; Mullen, J.E.; Kulasegaram, R.; Tong, C.Y. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 2005, 19, 1916-1919.
96. Turner, D.; Shahar, E.; Katchman, E.; Kedem, E.; Matus, N.; Katzir, M.; Hassoun, G.; Pollack, S.; Kessner, R.; Wainberg, M.A.; Avidor, B. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. J. Med. Virol. 2009, 81, 1509-1512.
97. Eshleman, S.H.; Hoover, D.R.; Chen, S.; Hudelson, S.E.; Guay, L.A.; Mwatha, A.; Fiscus, S.A.; Mmiro, F.; Musoke, P.; Jackson, J.B.; Kumwenda, N.; Taha, T. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J. Infect. Dis. 2005, 192, 30-36.
98. Eshleman, S.H.; Hoover, D.R.; Chen, S.; Hudelson, S.E.; Guay, L.A.; Mwatha, A.; Fiscus S.A.; Mmiro, F.; Musoke, P.; Jackson, J.B.; Kumwenda, N.; Taha, T. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005, 19, 2167-2169.
99. Flys, T.S.; Chen, S.; Jones, D.C.; Hoover, D.R.; Church, J.D.; Fiscus, S.A.; Mwatha, A.; Guay, L.A.; Mmiro, F.; Musoke, P. et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J. Acquir. Immune Defic. Syndr. 2006, 42, 610-613.
100. Conway, B.; Wainberg, M.A.; Hall, D.; Harris, M.; Reiss, P.; Cooper, D.; Vella, S.; Curry, R.; Robinson, P.; Lange, J.M.; Montaner, J.S. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001, 15, 1269-1274.
101. Collins, J.A.; Thompson, M.G.; Paintsil, E.; Ricketts, M.; Gedzior, J.; Alexander, L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. 2004, 78, 603-611.
102. Kantor, R.; Fessel, W.J.; Zolopa, A.R.; Israelski, D.; Shulman, N.; Montoya, J.G.; Harbour, M.; Schapiro, J.M.; Shafer, R.W. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob. Agents Chemother. 2002, 46, 1086-1092.
103. Mammano, F.; Trouplin, V.; Zennou, V.; Clavel, F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 2000, 74, 8524-8531.
104. Martinez-Picado, J.; Savara, A.V.; Sutton, L.; D'Aquila, R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73, 3744-3752.
105. Gonzalez, L.M.; Brindeiro, R.M.; Aguiar, R.S.; Pereira, H.S.; Abreu, C.M.; Soares, M.A.; Tanuri, A. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob. Agents Chemother. 2004, 48, 3552-3555.
106. Armstrong, K.L.; Lee T.H.; Essex, M. Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1. J. Virol. 2009, 83, 4051-4059.
107. van de Vijver, D.A.; Wensing, A.M.; Angarano, G.; Asjö, B.; Balotta, C.; Boeri, E.; Camacho, R.; Chaix, M.L.; Costagliola, D.; De Luca, A. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 2006, 41, 352-360.
108. Waléria-Aleixo, A.; Martins, A.N.; Arruda, M.B.; Brindeiro, R.M.; Da-Silva, R.M.; Nobre, F.F.; Greco, D.B.; Tanuri, A. Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns. Antimicrob. Agents Chemother. 2008, 52, 4497-502.
109. Dumans, A.T.; Soares, M.A.; Machado, E.S.; Hué, S.; Brindeiro, R.M.; Pillay, D.; Tanuri, A. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J. Infect. Dis. 2004, 189, 1232-1238.
110. Brenner, B.; Turner, D.; Oliveira, M.; Moisi, D.; Detorio, M.; Carobene, M.; Marlink, R.G,.; Schapiro, J.; Roger, M.; Wainberg, M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17, F1-F5.
111. Grossman, Z.; Istomin, V.; Averbuch, D.; Lorber, M.; Risenberg, K.; Levi, I.; Chowers, M.; Burke, M.; Bar Yaacov, N.; Schapiro, J.M.; Israel AIDS Multi-Center Study Group. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004, 18, 909-915.
112. Orrell, C.; Walensky, R.P.; Losina, E.; Pitt, J.; Freedberg, K.A.; Wood, R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir. Ther. 2009, 14, 523-531.
113. Wallis, C.; Sanne, I.; Venter, F.; Mellors, J.; Stevens, W. Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa. J. Acquir. Immune Defic. Syndr. 2009 (1 October 2009 Epub ahead of print).
114. Brenner, B.G.; Oliveira, M.; Doualla-Bell, F.; Moisi, D.D.; Ntemgwa, M.; Frankel, F.; Essex, M.; Wainberg, M.A. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20, F9-F13.
115. Ntemgwa, M.L.; Toni, T.; Brenner, B.G.; Oliveira, M.; Asahchop, E.L.; Moisi, D.; Wainberg, M.A. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob. Agents Chemother. 2009, 53, 708-715.
116. Coutsinos, D.; Invernizzi, C.F.; Xu, H.; Moisi, D.; Oliveira, M.; Brenner, B.G.; Wainberg, M.A. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J. Virol. 2009, 83, 2029-2033.
117. Turner, D.; Shahar, E.; Katchman, E.; Kedem, E.; Matus, N.; Katzir, M.; Hassoun, G.; Pollack, S.; Kessner, R.; Wainberg, M.A.; Avidor, B. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. J. Med. Virol. 2009, 81, 1509-1512.
118. Pillay, V.; Pillay, C.; Kantor, R.; Venter, F.; Levin, L.; Morris, L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 2008, 24, 1449-1454.
119. Doualla-Bell, F.; Avalos, A.; Brenner, B.; Gaolathe, T.; Mine, M.; Gaseitsiwe, S.; Oliveira, M.; Moisi, D.; Ndwapi, N.; Moffat, H. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob. Agents Chemother. 2006, 50, 4182-4185.
120. Soares, E.A.; Santos, A.F.; Sousa, T.M.; Sprinz, E.; Martinez, A.M.; Silveira, J.; Tanuri, A.; Soares, M.A. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One 2007, 2, e730.
121. Santos, A.F.; Abecasis, A.B.; Vandamme, A.M.; Camacho, R.J.; Soares, M.A. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J. Antimicrob. Chemother. 2009, 63, 593-599.
122. Abecasis, A.B.; Deforche, K.; Snoeck, J.; Bacheler, L.T.; McKenna, P.; Carvalho, A.P.; Gomes, P.; Camacho, R.J.; Vandamme, A.M. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005, 19, 1799-1806.
123. Gonzalez, L.M.; Santos, A.F.; Abecasis, A.B.; Van Laethem, K.; Soares, E.A.; Deforche, K.; Tanuri, A.; Camacho, R.; Vandamme, A.M.; Soares, M.A. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J. Antimicrob. Chemother. 2008, 61, 1201-1204.
124. Palma, A.C.; Abecasis, A.B.; Vercauteren, J.; Carvalho, A.P.; Cabanas, J.; Vandamme, A.M.; Camacho, R.J. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. Infect. Genet. Evol. 2009 (2 July 2009, Epub ahead of print).
125. Mitsuya, Y.; Winters, M.A.; Fessel, W.J.; Rhee, S.Y.; Hurley, L.; Horberg, M.; Schiffer, C.A.; Zolopa, A.R.; Shafer, R.W. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res. Hum. Retroviruses 2006, 22, 1300-1305.
126. Ziermann, R.; Limoli, K.; Das, K.; Arnold, E.; Petropoulos, C.J.; Parkin, N.T. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 2000, 74, 4414-4419.
127. Ode, H.; Matsuyama, S.; Hata, M.; Hoshino, T.; Kakizawa, J.; Sugiura, W. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations. J. Med. Chem. 2007, 50, 1768-1777.
128. Ode, H.; Matsuyama, S.; Hata, M.; Neya, S.; Kakizawa, J.; Sugiura, W.; Hoshino, T. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J. Mol. Biol. 2007, 370, 598-607.
129. Soares, E.A.; Santos, A.F.; Gonzalez, L.M.; Lalonde, M.S.; Tebit, D.M.; Tanuri, A.; Arts, E.J.; Soares, M.A. Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J. Antimicrob. Chemother. 2009, 64, 938-944.
130. Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Maldarelli, F.; Hase, S.; Takebe, Y.; Pathak, V.K. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. J. Virol. 2009, 83, 8502-8513.
131. Frater, A.J.; Dunn, D.T.; Beardall, A.J.; Ariyoshi, K.; Clarke, J.R.; McClure, M.O.; Weber, J.N. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002, 16, 1139-1146.
132. Bocket, L.; Cheret, A.; Deuffic-Burban, S.; Choisy, P.; Gerard, Y.; de la Tribonnière, X.; Viget, N.; Ajana, F.; Goffard, A.; Barin, F.; Mouton, Y.; Yazdanpanah, Y. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir. Ther. 2005, 10, 247-254.
133. Alexander, C.S.; Montessori, V.; Wynhoven, B.; Dong, W.; Chan, K.; O'Shaughnessy, M.V.; Mo, T.; Piaseczny, M.; Montaner, J.S.; Harrigan, P.R. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir. Ther. 2002, 7, 31-35.
134. De Wit, S.; Boulmé, R.; Poll, B.; Schmit, J.C.; Clumeck, N. Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B vs. non-B treatment-naive HIV-1 patients. AIDS 2004, 18, 2330-2331.
135. Bannister, W.P.; Ruiz, L.; Loveday, C.; Vella, S.; Zilmer, K.; Kjaer, J.; Knysz, B.; Phillips, A.N.; Mocroft, A.; EuroSIDA Study Group. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir. Ther. 2006, 11, 707-715.
136. Garrido, C.; Zahonero, N.; Fernándes, D.; Serrano, D.; Silva, A.R.; Ferraria, N.; Antúnes, F.; González-Lahoz, J.; Soriano, V.; de Mendoza, C. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J. Antimicrob. Chemother. 2008, 61, 694-698.
137. Geretti, A.M.; Harrison, L.; Green, H.; Sabin, C.; Hill, T.; Fearnhill, E.; Pillay, D.; Dunn, D.; UK Collaborative Group on HIV Drug Resistance. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin. Infect. Dis. 2009, 48, 1296-1305.
138. Atlas, A.; Granath, F.; Lindstrom, A.; Lidman, K.; Lindbacl, S.; Alaeus, A. Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res. Hum. Retroviruses 2005, 21, 221-227.
139. Ruelle, J; Roman, F.; Vandenbroucke, A.T.; Lambert C.; Fransen, K.; Echahidi, F.; Piérard, D.; Verhofstede, C.; Van Laethem, K.; Delforge, M.L.; Vaira, D.; Schmit, J.C.; Goubau, P. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infec. Dis. 2008, 8, 21.